High incidence of neutropenia in patients with prolonged ceftaroline exposure
Open Access
- 13 April 2016
- journal article
- research article
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 71 (7) , 2010-2013
Abstract
We sought to determine the rate of incident neutropenia and identify potential clinical factors associated with incident neutropenia among patients treated with long courses of ceftaroline. We retrospectively identified adult patients who received ceftaroline for ≥7 days consecutively at two large academic medical centres in Boston, USA between November 2010 and March 2015. Clinical characteristics (age, gender, medication allergies, baseline renal function, duration of ceftaroline exposure, total daily ceftaroline dose, body mass-adjusted ceftaroline dose and development of rash and neutropenia) were recorded and the rate of incident neutropenia was calculated. The Naranjo probability scale was used to assess whether ceftaroline exposure was associated with neutropenia. We assessed whether clinical factors were associated with neutropenia. The overall rate of incident neutropenia was 10%–14% with ≥2 weeks and 21% with ≥3 weeks of ceftaroline exposure. The median duration of ceftaroline exposure [26 days (IQR 22–44; range 13–68) in patients who developed neutropenia and 15 days (IQR 9–29; range 7–64) in patients without neutropenia] was associated with incident neutropenia (P = 0.048). The median total number of ceftaroline doses received [63 (IQR 44–126; range 36–198) by neutropenic patients and 32 (IQR 22–63; range 14–180) by non-neutropenic patients] was also associated with incident neutropenia (P = 0.023). The overall rate of neutropenia was high and associated with duration of ceftaroline exposure and total number of doses received. Close laboratory monitoring is warranted with long-term ceftaroline use.Keywords
Funding Information
- Brigham and Women's Physicians Organization
- National Institutes of Health (K23 AI097225)
This publication has 11 references indexed in Scilit:
- Use of ceftaroline after glycopeptide failure to eradicate meticillin-resistant Staphylococcus aureus bacteraemia with elevated vancomycin minimum inhibitory concentrationsInternational Journal of Antimicrobial Agents, 2014
- A case of profound neutropenia and agranulocytosis associated with off-label use of ceftarolineAmerican Journal of Health-System Pharmacy, 2014
- High Incidence of Discontinuations Due to Adverse Events in Patients Treated with CeftarolinePharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2014
- Ceftaroline - a cause for neutropeniaJournal of Clinical Pharmacy and Therapeutics, 2013
- The use of ceftaroline fosamil in methicillin-resistant Staphylococcus aureus endocarditis and deep-seated MRSA infections: a retrospective case series of 10 patientsJournal of Infection and Chemotherapy, 2013
- Methicillin-resistant Staphylococcus aureus bacteraemia and endocarditis treated with ceftaroline salvage therapyJournal of Antimicrobial Chemotherapy, 2012
- Incidence of Neutropenia during Treatment of Bone-Related Infections with Piperacillin-TazobactamClinical Infectious Diseases, 2003
- Incidence of β-Lactam–Induced Delayed Hypersensitivity and Neutropenia During Treatment of Infective EndocarditisArchives of internal medicine (1960), 1999
- A prospective study of neutropenia induced by high doses of β-lactam antibioticsJournal of Antimicrobial Chemotherapy, 1990
- A method for estimating the probability of adverse drug reactionsClinical Pharmacology & Therapeutics, 1981